Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 27, 2024
Data Byte
Junshi’s PD-1 among seven new products recommended by EMA’s CHMP
Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions
BioCentury | Jan 23, 2023
Deals
CinCor, Albireo each received higher bids in 2022 before this month’s M&A deals
Biotechs had sweeter offers, then accepted smaller proposals after share prices fell
BioCentury | Jan 9, 2023
Deals
CVRs address risks in billion-dollar AZ-CinCor, Ipsen-Albireo deals
Pair of high-premium M&A transactions could deliver shareholders more value tied to regulatory milestones
BioCentury | Sep 22, 2021
Product Development
Sept. 21 Quick Takes: FDA nod for Incyte’s topical JAK
Plus Mirum’s partner in Japan, a Boehringer deal in tumor antigens, an early readout for Stoke and more
BioCentury | Jan 26, 2021
Regulation
Jan. 25 Quick Takes: Comirnaty approved in Australia, authorized in Hong Kong; plus Albireo, Iterum and AZ
Comirnaty (BNT162b2) from BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) received provisional approval from the Australian Therapeutic Goods Administration and emergency use authorization
BioCentury | Aug 19, 2020
Finance
Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo
Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New
BioCentury | Jul 13, 2019
Finance
How crossover, insider support and big money correlated with performance across 1H19 IPOs
Big money and crossover support continue to drive IPO performance in 1H19
Items per page:
1 - 10 of 46